Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Pain

Treatments: Drug: AZD2066

Study type: Interventional

Funder types: Industry

Identifiers

NCT00829088

D0475C00008

EudractCT No: 2008-006129-14

Details and patient eligibility

About

The aim of this study is to get information about absorption, distribution, metabolism and excretion as well as the tolerability and safety of AZD2066 in healthy male volunteers.

Enrollment: 6 patients

Sex: Male

Ages: 35 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Provision of signed informed consent
• Clinically normal physical findings and laboratory values as judged by the investigator and a normal resting ECG.

Exclusion criteria

• History of somatic disease/condition, which may interfere with the objectives of the study.
• History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder.
• Healthy volunteers who have been exposed to radiation levels above background (eg, through X-ray examinations).